During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix”) today announces that its next-generation PSMA1 PET2 imaging ...

New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated ...

STAMPEDE otherwise follows a line of randomized trials (e.g., MAST, TAXOMET, IMPROVE) that have failed to prove cancer ...

Dr. Kevin O’Connor invoked doctor-client privilege and his rights under the Fifth Amendment during an appearance before the ...

Prostate cancer is one of the most common cancers found in U.S. men. If detected early, prostate cancer is often highly treatable before it spreads. But the American Cancer Society estimates there ...